CriticalSynthetic opioid, full mu-receptor agonist×Selective irreversible monoamine oxidase B inhibitor
Updated · Methodology
Mechanism
Rasagiline is a potent, irreversible inhibitor of monoamine oxidase (MAO) type B (rasagiline summary of product characteristics, SmPC, European Medicines Agency, EMA, section 5.1). MAO breaks down catecholamines and serotonin in the nervous system and other tissues (rasagiline label, US Food and Drug Administration, FDA, section 12.1). At recommended doses rasagiline acts selectively on MAO-B, but this selectivity falls as the dose rises above the recommended range (FDA rasagiline label, sections 5.1 and 12.1). Methadone is a synthetic opioid and a pure opioid receptor agonist (methadone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). According to the Spanish methadone SmPC, MAO inhibitors can increase and prolong the depressant effects of methadone or stimulate the central nervous system, and serotonin syndrome can occur with them (methadone SmPC, AEMPS, section 4.5). According to the US methadone label, interactions of MAO inhibitors with opioids may present as serotonin syndrome or opioid toxicity (FDA methadone label, section 7). At therapeutic concentrations rasagiline is unlikely to affect drugs metabolised by the cytochrome P450 (CYP) enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 (rasagiline SmPC, EMA, section 4.5), and these enzymes, together with CYP2B6, metabolise methadone (FDA methadone label, section 12.3).
Symptoms
Serotonin syndrome with methadone and monoamine oxidase (MAO) inhibitors or other serotonergic drugs presents with mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high temperature), neuromuscular changes (overactive reflexes, poor coordination, rigidity), nausea, vomiting and diarrhoea. It usually starts within several hours to a few days of combined use, but may start later (methadone label, US Food and Drug Administration, FDA, section 5.9). Serotonin syndrome has also been reported with rasagiline and methadone, and it can be fatal (FDA rasagiline label, section 5.2). According to the European rasagiline summary of product characteristics (SmPC), post-marketing reports describe potentially fatal serotonin syndrome with agitation, confusion, rigidity, fever and myoclonus in patients who took rasagiline with methadone, tramadol, pethidine, propoxyphene or antidepressants (rasagiline SmPC, European Medicines Agency, EMA, section 4.8). The other form of this interaction is opioid toxicity with respiratory depression and coma (FDA methadone label, section 7). According to the Spanish methadone SmPC, MAO inhibitors can also increase and prolong the depressant effects of methadone or stimulate the central nervous system (methadone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5).
Management
The combination is contraindicated. The Spanish methadone summaries of product characteristics (SmPCs) prohibit combining methadone with monoamine oxidase (MAO) inhibitors or starting it within 2 weeks of stopping them (methadone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). According to its own SmPC, rasagiline is an MAO type B inhibitor (rasagiline SmPC, European Medicines Agency, EMA, section 5.1). The US rasagiline label contraindicates methadone by name (rasagiline label, US Food and Drug Administration, FDA, section 4). The US methadone label is milder: it does not recommend methadone in patients taking MAO inhibitors or within 14 days of stopping them (FDA methadone label, section 7). The European rasagiline SmPC contraindicates only pethidine among opioids, but its adverse reactions section reports serotonin syndrome with methadone (rasagiline SmPC, EMA, sections 4.3 and 4.8). Start methadone no earlier than 2 weeks after stopping rasagiline (methadone SmPC, AEMPS, sections 4.3 and 4.5; FDA rasagiline label, section 4), and do not start an MAO inhibitor while the patient is taking methadone (FDA methadone label, section 17). The documents give no interval between the last dose of methadone and the first rasagiline tablet. If serotonin syndrome is suspected, stop methadone (FDA methadone label, section 5.9). Warn patients taking rasagiline that pethidine and some other painkillers must not be used with it (FDA rasagiline label, section 17).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Azilect (rasagiline) prescribing information – contraindications with sympathomimetics (2014)– FDA Azilect label, Drug Interactions §7.1; concurrent triptan use cautioned; DailyMed setid a40d0e73-3f9f-4b01-979d-402c9cdaeb60
- FDA: Methadone hydrochloride tablets (methadone) prescribing information (2025)– FDA, DailyMed setid 4a44bde6-c348-4316-b0e0-c24b407cb823 (VistaPharm), versión 17, revisión 12/2025, secciones 5.4, 5.9 y 7
- EMA: Ficha técnica: Rasagilina – Azilect (EU/1/04/304), sección 4.5 (2025)– EMA, SmPC Azilect 1 mg (EU/1/04/304), texto en CIMA nº 04304004, consultado 19.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 5.1 y 5.2
- AEMPS: Ficha técnica: Metadona, Metasedin 40 mg comprimidos (nº registro 62423), sección 4.3 (2026)– AEMPS, CIMA, nº registro 62423 (Metasedin 40 mg comprimidos, Esteve Pharmaceuticals), revisión 05/2026, secciones 4.3, 4.5 y 5.1